MedTrace Logo

Patient's Anastrozole Compliance to Therapy Programme

NCT00555867 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4923

Last updated 2011-12-23

No results posted yet for this study

Summary

Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS). The clinic and approximately 7 office based physicians will collaborate within their breast centre networks to conduct this program. A breast centre network should be able to recruit in this program approximately 80 patients (approximately 40 patients per year). It is planned to enroll approximately 4674 patients in this NIS (2337 patients per arm). The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for upfront adjuvant endocrine treatment with anastrozole according to the current standard medical procedures.

Conditions

Interventions

DRUG

Anastrozole

oral

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Germany Medical Director · AstraZeneca

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-02-28
Completion
2011-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555867 on ClinicalTrials.gov